1
|
Powell WH, Annett LE, Depoortere R, Newman-Tancredi A, Iravani MM. The selective 5-HT 1A receptor agonist NLX-112 displays anxiolytic-like activity in mice. NAUNYN-SCHMIEDEBERG'S ARCHIVES OF PHARMACOLOGY 2022; 395:149-157. [PMID: 34821958 DOI: 10.1007/s00210-021-02183-2] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 06/28/2021] [Accepted: 11/10/2021] [Indexed: 10/19/2022]
Abstract
Anxiety is amongst the commonest neuropsychiatric disorders, and there is a large body of evidence to suggest that abnormalities in serotonergic function are involved in its pathogenesis. Several studies have implicated 5-HT1A receptor activation in mitigating anxiety disorders, so this study investigated the acute effects of a highly selective, potent and efficacious 5-HT1A receptor full agonist, NLX-112 (a.k.a. befiradol, F13640), in middle-aged C57bl/6 J male mice. Video tracking was used to measure several parameters including time spent in the open and closed arms of an elevated plus maze (EPM), distance travelled and thigmotaxis in an open field test (OFT). At 0.1 to 1.0 mg/kg s.c., NLX-112 markedly decreased thigmotaxis and increased exploratory behaviour in the OFT and EPM assays. Hence, at 0.3 mg/kg, NLX-112 augmented locomotor activity in the centre of an open field arena by 164% and increased the time spent in the open arms of the EPM by 119% of control. These results indicate that anxiety-like behaviours in mice are significantly diminished with low doses of NLX-112. NLX-112 may therefore possess anxiolytic properties which complement its known activity in models of movement disorders.
Collapse
Affiliation(s)
- William H Powell
- Department of Clinical Pharmaceutical and Biological Science, University of Hertfordshire, Hatfield, UK
| | - Lucy E Annett
- Department of Psychology, School of Life and Medical Sciences, College Lane, University of Hertfordshire, Hatfield, AL10 9AB, UK
| | | | | | - Mahmoud M Iravani
- Department of Clinical Pharmaceutical and Biological Science, University of Hertfordshire, Hatfield, UK.
| |
Collapse
|
2
|
Coimbra NC, Paschoalin-Maurin T, Bassi GS, Kanashiro A, Biagioni AF, Felippotti TT, Elias-Filho DH, Mendes-Gomes J, Cysne-Coimbra JP, Almada RC, Lobão-Soares B. Critical neuropsychobiological analysis of panic attack- and anticipatory anxiety-like behaviors in rodents confronted with snakes in polygonal arenas and complex labyrinths: a comparison to the elevated plus- and T-maze behavioral tests. ACTA ACUST UNITED AC 2017; 39:72-83. [PMID: 28177062 PMCID: PMC7112733 DOI: 10.1590/1516-4446-2015-1895] [Citation(s) in RCA: 30] [Impact Index Per Article: 4.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/01/2016] [Accepted: 04/04/2016] [Indexed: 01/02/2023]
Abstract
Objective: To compare prey and snake paradigms performed in complex environments to the elevated plus-maze (EPM) and T-maze (ETM) tests for the study of panic attack- and anticipatory anxiety-like behaviors in rodents. Methods: PubMed was reviewed in search of articles focusing on the plus maze test, EPM, and ETM, as well as on defensive behaviors displayed by threatened rodents. In addition, the authors' research with polygonal arenas and complex labyrinth (designed by the first author for confrontation between snakes and small rodents) was examined. Results: The EPM and ETM tests evoke anxiety/fear-related defensive responses that are pharmacologically validated, whereas the confrontation between rodents and snakes in polygonal arenas with or without shelters or in the complex labyrinth offers ethological conditions for studying more complex defensive behaviors and the effects of anxiolytic and panicolytic drugs. Prey vs. predator paradigms also allow discrimination between non-oriented and oriented escape behavior. Conclusions: Both EPM and ETM simple labyrinths are excellent apparatuses for the study of anxiety- and instinctive fear-related responses, respectively. The confrontation between rodents and snakes in polygonal arenas, however, offers a more ethological environment for addressing both unconditioned and conditioned fear-induced behaviors and the effects of anxiolytic and panicolytic drugs.
Collapse
Affiliation(s)
- Norberto C Coimbra
- Laboratório de Neuroanatomia e Neuropsicobiologia, Departamento de Farmacologia, Faculdade de Medicina de Ribeirão Preto (FMRP), Universidade de São Paulo (USP), Ribeirão Preto, SP, Brazil.,Instituto de Neurociências e Comportamento (INeC), Ribeirão Preto, SP, Brazil.,Núcleo de Pesquisa em Neurobiologia das Emoções (NAP-USP-NuPNE), FMRP, USP, Ribeirão Preto, SP, Brazil
| | - Tatiana Paschoalin-Maurin
- Laboratório de Neuroanatomia e Neuropsicobiologia, Departamento de Farmacologia, Faculdade de Medicina de Ribeirão Preto (FMRP), Universidade de São Paulo (USP), Ribeirão Preto, SP, Brazil.,Núcleo de Pesquisa em Neurobiologia das Emoções (NAP-USP-NuPNE), FMRP, USP, Ribeirão Preto, SP, Brazil
| | - Gabriel S Bassi
- Laboratório de Neuroanatomia e Neuropsicobiologia, Departamento de Farmacologia, Faculdade de Medicina de Ribeirão Preto (FMRP), Universidade de São Paulo (USP), Ribeirão Preto, SP, Brazil
| | - Alexandre Kanashiro
- Laboratório de Neuroanatomia e Neuropsicobiologia, Departamento de Farmacologia, Faculdade de Medicina de Ribeirão Preto (FMRP), Universidade de São Paulo (USP), Ribeirão Preto, SP, Brazil
| | - Audrey F Biagioni
- Laboratório de Neuroanatomia e Neuropsicobiologia, Departamento de Farmacologia, Faculdade de Medicina de Ribeirão Preto (FMRP), Universidade de São Paulo (USP), Ribeirão Preto, SP, Brazil.,Núcleo de Pesquisa em Neurobiologia das Emoções (NAP-USP-NuPNE), FMRP, USP, Ribeirão Preto, SP, Brazil
| | - Tatiana T Felippotti
- Laboratório de Neuroanatomia e Neuropsicobiologia, Departamento de Farmacologia, Faculdade de Medicina de Ribeirão Preto (FMRP), Universidade de São Paulo (USP), Ribeirão Preto, SP, Brazil.,Instituto de Neurociências e Comportamento (INeC), Ribeirão Preto, SP, Brazil
| | - Daoud H Elias-Filho
- Laboratório de Neuroanatomia e Neuropsicobiologia, Departamento de Farmacologia, Faculdade de Medicina de Ribeirão Preto (FMRP), Universidade de São Paulo (USP), Ribeirão Preto, SP, Brazil.,Instituto de Neurociências e Comportamento (INeC), Ribeirão Preto, SP, Brazil
| | - Joyce Mendes-Gomes
- Laboratório de Neuroanatomia e Neuropsicobiologia, Departamento de Farmacologia, Faculdade de Medicina de Ribeirão Preto (FMRP), Universidade de São Paulo (USP), Ribeirão Preto, SP, Brazil.,Instituto de Neurociências e Comportamento (INeC), Ribeirão Preto, SP, Brazil.,Núcleo de Pesquisa em Neurobiologia das Emoções (NAP-USP-NuPNE), FMRP, USP, Ribeirão Preto, SP, Brazil
| | - Jade P Cysne-Coimbra
- Laboratório de Neuroanatomia e Neuropsicobiologia, Departamento de Farmacologia, Faculdade de Medicina de Ribeirão Preto (FMRP), Universidade de São Paulo (USP), Ribeirão Preto, SP, Brazil
| | - Rafael C Almada
- Laboratório de Neuroanatomia e Neuropsicobiologia, Departamento de Farmacologia, Faculdade de Medicina de Ribeirão Preto (FMRP), Universidade de São Paulo (USP), Ribeirão Preto, SP, Brazil.,Instituto de Neurociências e Comportamento (INeC), Ribeirão Preto, SP, Brazil.,Núcleo de Pesquisa em Neurobiologia das Emoções (NAP-USP-NuPNE), FMRP, USP, Ribeirão Preto, SP, Brazil
| | - Bruno Lobão-Soares
- Laboratório de Neuroanatomia e Neuropsicobiologia, Departamento de Farmacologia, Faculdade de Medicina de Ribeirão Preto (FMRP), Universidade de São Paulo (USP), Ribeirão Preto, SP, Brazil.,Departamento de Biofísica e Farmacologia, Universidade Federal do Rio Grande do Norte (UFRN), Natal, RN, Brazil
| |
Collapse
|
3
|
Psychopharmacological characterisation of the successive negative contrast effect in rats. Psychopharmacology (Berl) 2015; 232:2697-709. [PMID: 25791190 PMCID: PMC4502301 DOI: 10.1007/s00213-015-3905-2] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 11/20/2014] [Accepted: 02/23/2015] [Indexed: 11/27/2022]
Abstract
RATIONALE Successive negative contrast (SNC) describes a change in the behaviour of an animal following a downshift in the quantitative or qualitative value of an expected reward. This behavioural response has been hypothesised to be linked to affective state, with negative states associated with larger and/or prolonged shifts in behaviour. OBJECTIVE This study has investigated whether different psychopharmacological treatments have dissociable actions on the SNC effect in rats and related these findings to their actions on different neurotransmitter systems and affective state. METHODS Animals were trained to perform a nose-poke response to obtain a high-value food reward (four pellets). SNC was quantified during devalue sessions in which the reward was reduced to one pellet. Using a within-subject study design, the effects of acute treatment with anxiolytic, anxiogenic, antidepressant and dopaminergic drugs were investigated during both baseline (four pellets) or devalue sessions (one pellet). RESULTS The indirect dopamine agonist, amphetamine, attenuated the SNC effect whilst the D1/D2 antagonist, alpha-flupenthixol, potentiated it. The antidepressant citalopram, anxiolytic buspirone and anxiogenic FG7142 had no specific effects on SNC, although FG7142 induced general impairments at higher doses. The α2-adrenoceptor antagonist, yohimbine, increased premature responding but had no specific effect on SNC. Results for the anxiolytic diazepam were mixed with one group showing an attenuation of the SNC effect whilst the other showed no effect. CONCLUSIONS These data suggest that the SNC effect is mediated, at least in part, by dopamine signalling. The SNC effect may also be attenuated by benzodiazepine anxiolytics.
Collapse
|
5
|
Volk B, Gacsályi I, Pallagi K, Poszávácz L, Gyönös I, Szabó É, Bakó T, Spedding M, Simig G, Szénási G. Optimization of (Arylpiperazinylbutyl)oxindoles Exhibiting Selective 5-HT7 Receptor Antagonist Activity. J Med Chem 2011; 54:6657-69. [DOI: 10.1021/jm200547z] [Citation(s) in RCA: 37] [Impact Index Per Article: 2.8] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/25/2022]
Affiliation(s)
- Balázs Volk
- Chemical Research Division, EGIS Pharmaceuticals Plc., P.O. Box 100, Budapest, H-1475 Hungary
| | - István Gacsályi
- Preclinical Research Division, EGIS Pharmaceuticals Plc., P.O. Box 100, Budapest, H-1475 Hungary
| | - Katalin Pallagi
- Preclinical Research Division, EGIS Pharmaceuticals Plc., P.O. Box 100, Budapest, H-1475 Hungary
| | - László Poszávácz
- Chemical Research Division, EGIS Pharmaceuticals Plc., P.O. Box 100, Budapest, H-1475 Hungary
| | - Ildikó Gyönös
- Preclinical Research Division, EGIS Pharmaceuticals Plc., P.O. Box 100, Budapest, H-1475 Hungary
| | - Éva Szabó
- Preclinical Research Division, EGIS Pharmaceuticals Plc., P.O. Box 100, Budapest, H-1475 Hungary
| | - Tibor Bakó
- Chemical Research Division, EGIS Pharmaceuticals Plc., P.O. Box 100, Budapest, H-1475 Hungary
| | - Michael Spedding
- Les Laboratoires Servier, 22 rue Garnier, 92578 Neuilly-sur-Seine, France
| | - Gyula Simig
- Chemical Research Division, EGIS Pharmaceuticals Plc., P.O. Box 100, Budapest, H-1475 Hungary
| | - Gábor Szénási
- Preclinical Research Division, EGIS Pharmaceuticals Plc., P.O. Box 100, Budapest, H-1475 Hungary
| |
Collapse
|
6
|
Anxiolytic effects of nicotine in a rodent test of approach-avoidance conflict. Psychopharmacology (Berl) 2009; 204:541-9. [PMID: 19241061 PMCID: PMC2920299 DOI: 10.1007/s00213-009-1486-7] [Citation(s) in RCA: 30] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 03/13/2008] [Accepted: 01/31/2009] [Indexed: 02/05/2023]
Abstract
RATIONALE Nicotine has been reported to produce both anxiolytic and/or anxiogenic effects in humans and animals. OBJECTIVES This study examined whether pretreatment with nicotine would alter anxiety in a unique runway model of approach-avoidance conflict. MATERIALS AND METHODS Food-restricted rats were trained to run a straight alley once a day to obtain food upon goal-box entry. Beginning on trial 11, food reward was followed by a series of five foot shocks (0.3-0.4 mA, 0.5 s) in the goal box. Non-shocked control rats continued to run for food only. The resulting association of the goal box with both a positive (food) and negative (foot shock) stimulus produced an approach-avoidance conflict (subjects exhibited "retreat behaviors" in which they would approach the goal box, stop, and then retreat back towards the start box). Once retreats were established, their sensitivity to nicotine pretreatment (0.0, 0.03, 0.045, 0.06, or 0.075 mg/kg, i.v.) was compared to saline. In subsequent tests, the effects of nicotine (0.06 or 0.03 mg/kg) were examined on spontaneous activity (locomotion) and center-square entries in an open field (anxiety). RESULTS Doses of 0.06 and 0.075 mg/kg, but not lower doses of nicotine, reduced the number of runway retreats, and 0.06 mg/kg nicotine increased the number of open-field center entries relative to saline. No effects on locomotion were observed. CONCLUSIONS Nicotine reduced approach-avoidance conflict and increased the rats' willingness to enter the center of an open field, suggesting that the drug can produce anxiolytic properties and that such effects may serve as an important factor in the persistence of smoking behavior.
Collapse
|
7
|
Treit D, Engin E, McEown K. Animal models of anxiety and anxiolytic drug action. Curr Top Behav Neurosci 2009; 2:121-60. [PMID: 21309109 DOI: 10.1007/7854_2009_17] [Citation(s) in RCA: 38] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/06/2023]
Abstract
Animal models of anxiety attempt to represent some aspect of the etiology, symptomatology, or treatment of human anxiety disorders, in order to facilitate their scientific study. Within this context, animal models of anxiolytic drug action can be viewed as treatment models relevant to the pharmacological control of human anxiety. A major purpose of these models is to identify novel anxiolytic compounds and to study the mechanisms whereby these compounds produce their anxiolytic effects. After a critical analysis of "face," "construct," and "predictive" validity, the biological context in which animal models of anxiety are to be evaluated is specified. We then review the models in terms of their general pharmacological profiles, with particular attention to their sensitivity to 5-HTIA agonists and antidepressant compounds. Although there are important exceptions, most of these models are sensitive to one or perhaps two classes of anxiolytic compounds, limiting their pharmacological generality somewhat, but allowing in depth analysis of individual mechanisms of anxiolytic drug action (e.g., GABAA agonism). We end with a discussion of possible sources of variability between models in response to 5-HTIA agonists and antidepressant drugs.
Collapse
Affiliation(s)
- Dallas Treit
- Department of Psychology, Division of Neuroscience, University of Alberta, P-449 Biological Sciences Building, Edmonton, AB, Canada T6G 2E9.
| | | | | |
Collapse
|
9
|
Shoblock JR. The pharmacology of Ro 64-6198, a systemically active, nonpeptide NOP receptor (opiate receptor-like 1, ORL-1) agonist with diverse preclinical therapeutic activity. CNS DRUG REVIEWS 2007; 13:107-36. [PMID: 17461893 PMCID: PMC6494153 DOI: 10.1111/j.1527-3458.2007.00007.x] [Citation(s) in RCA: 42] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 12/31/2022]
Abstract
The NOP receptor (formerly referred to as opiate receptor-like 1, ORL-1, LC132, OP(4), or NOP(1)) is a G protein-coupled receptor that shares high homology to the classic opioid MOP, DOP, and KOP (mu, delta, and kappa, respectively) receptors and was first cloned in 1994 by several groups. The NOP receptor remained an orphan receptor until 1995, when the endogenous neuropeptide agonist, known as nociceptin or orphanin FQ (N/OFQ) was isolated. Five years later, a group at Hoffmann-La Roche reported on the selective, nonpeptide NOP agonist Ro 64-6198, which became the most extensively published nonpeptide NOP agonist and a valuable pharmacological tool in determining the potential of the NOP receptor as a therapeutic target. Ro 64-6198 is systemically active and achieves high brain penetration. It has subnanomolar affinity for the NOP receptor and is at least 100 times more selective for the NOP receptor over the classic opioid receptors. Ro 64-6198 ranges from partial to full agonist, depending on the assay. Preclinical data indicate that Ro 64-6198 may have broad clinical uses, such as in treating stress and anxiety, addiction, neuropathic pain, cough, and anorexia. This review summarizes the pharmacology and preclinical data of Ro 64-6198.
Collapse
Affiliation(s)
- James R Shoblock
- Johnson and Johnson Pharmaceutical Research and Development, LLC, San Diego, California 92121, USA.
| |
Collapse
|